EMA Calls for Restricted Use of Xeljanz, Rinvoq, Similar Drugs Due to Heart, Cancer, Blood Clot and Infection Risks
European regulators urge doctors to limit the use of Xeljanz and similar drugs among certain patients more prone to heart problems and blood clots.